跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT03784079
NCT03784079已完成2 期

A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatment-Naïve Adults

ViiV Healthcare1 个研究点 分布在 1 个国家目标入组 34 人开始时间: 2019年1月31日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
34
试验地点
1
主要终点
Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Infection with HIV-1 continues to be a serious health threat throughout the world. Chronic exposure to combination anti-retroviral therapy identified anti-retroviral associated long-term toxicities. Hence, there is a need to prevent these co-morbidities. GSK3640254 is a next-generation HIV-1 Maturation Inhibitor (MI) which may be effective for HIV-1 infection. This study will evaluate the antiviral effect, safety, tolerability and pharmacokinetics/ pharmacodynamics of GSK3640254 in HIV-1 infected treatment-naive adults. This study will consists of two parts; Part 1 and Part 2. Part 1 will evaluate two active doses of GSK3640254, 200 milligrams (mg) (Cohort 1) and 10 mg (Cohort 2) along with placebo to match GSK3640254 Mesylate salt. Part 2 will evaluate three active doses of GSK3640254. Dose level 1 of GSK3640254 that can provide at least 30 percent of the maximum effect (Cohort 1), dose level 2 of GSK3640254 that can provide at least 75 percent of the maximum effect (Cohort 2) and dose level 3 of GSK3640254 that can provide at least 90 percent of the maximum effect (Cohort 3). These doses are anticipated to be 5 mg, 40 mg and 100 mg respectively, but could be modified based on data obtained in Part 1. Subjects will also receive placebo to match GSK3640254 Mesylate salt in Part 2 of the study. All doses will be administered after a moderate fat meal. This study will consist of Screening period (up to 14 days), Treatment period (Day 1- Day 10), post-dose Follow-up (Day 11- Day 17) and final Follow-up (Day 18-24). A total of approximately 34 subjects will be enrolled, of which, 14 subjects will be randomized in Part 1 and 20 in Part 2 of the study. Six subjects will be enrolled in each of the active dose cohorts and 2 subjects will be enrolled in each of the placebo cohorts.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

This will be a double blind study. Subjects and investigator will be blinded.

入排标准

年龄范围
18 Years 至 65 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Subject must be 18 to 65 years of age inclusive, at the time of signing the informed consent.
  • •Subjects who are healthy (other than HIV infection) as determined by the Investigator or medically qualified designee based on a medical evaluation including medical history, laboratory tests, and cardiac monitoring.
  • •Screening Cluster of designation 4 positive (CD4+) T-cell count >=350 cells per millimeter cube (cells/mm^3).
  • •Documented HIV infection and Screening plasma HIV-1 RNA >=5000 copies/milliliter (mL). A single repeat of this test is allowed within a single Screening period to determine eligibility.
  • •Treatment-naive: No anti-retrovirals (in combination or monotherapy) received after the diagnosis of HIV-1 infection.
  • •Body weight >=50.0 kilograms (kg) (110 Pounds) for men and >=45.0 kg (99 pounds) for women and body mass index (BMI) within the range 18.5-31.0 kg/meter square (kg/m^2) (inclusive).
  • •A female subject is eligible to participate if she is not pregnant, not breastfeeding, and not a woman of childbearing potential (WOCBP).
  • •Capable of giving signed informed consent.
  • •For subjects enrolled in France: a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

排除标准

  • •Presence of Hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to starting study treatment.
  • •Positive Hepatitis C antibody test result at screening or within 3 months prior to starting study treatment and positive on reflex to Hepatitis C RNA.
  • •ALT >2 times upper limit of normal (ULN). A single repeat of ALT is allowed within a single Screening period to determine eligibility.
  • •Bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent).
  • •Subjects with primary HIV infection, evidenced by acute retroviral syndrome (example given [e.g.], fever, malaise, fatigue, etc) and/or evidence of recent (within 3 months) documented viremia without antibody production and/or evidence of recent (within 3 months) documented seroconversion.
  • •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones);
  • •A pre-existing condition interfering with normal gastrointestinal anatomy or motility (e.g., gastroesophageal reflux disease [GERD], gastric ulcers, gastritis), hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs or render the subject unable to take oral study treatment.
  • •Any acute laboratory abnormality at screen which, in the opinion of the investigator, should preclude participation in the study of an investigational compound.
  • •Any Grade 2-4 laboratory abnormality at screen, with the exception of creatine phosphokinase (CPK) and lipid abnormalities (e.g., total cholesterol, triglycerides, etc), and ALT (described above), will exclude a subject from the study unless the investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the sponsor. A single repeat of any lab abnormality is allowed within a single screening period to determine eligibility.
  • •Any history of significant underlying psychiatric disorder, including but not limited to schizophrenia, bipolar disorder with or without psychotic symptoms, other psychotic disorders, or schizotypal (personality) disorder.
  • •Any history of major depressive disorder with or without suicidal features, or anxiety disorders, that required medical intervention (pharmacologic or not) such as hospitalization or other inpatient treatment and/or chronic (>6 months) outpatient treatment. Subjects with other conditions such as adjustment disorder or dysthymia that have required shorter term medical therapy (<6 months) without inpatient treatment and are currently well-controlled clinically or resolved may be considered for entry after discussion and agreement with the ViiV Medical Monitor.
  • •Any pre-existing physical or other psychiatric condition (including alcohol or drug abuse), which, in the opinion of the investigator (with or without psychiatric evaluation), could interfere with the subject's ability to comply with the dosing schedule and protocol evaluations or which might compromise the safety of the subject.
  • •Medical history of cardiac arrhythmias or cardiac disease or a family or personal history of long QT syndrome.
  • •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
  • •The subject has participated in a clinical trial and has received an investigational product within the 30 days prior to the first dosing day in the current study.
  • •Any positive (abnormal) response confirmed by the investigator on a Screening clinician- (or qualified designee-) administered Columbia Suicide Severity Rating Scale (CSSRS).
  • •Any positive result for illicit drug use (e.g., cocaine, heroin) at Screening. A positive screen for marijuana is not exclusionary, though if positive for delta-9-tetrahydrocannabinol (THC).
  • •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
  • •Exposure to more than four new investigational drugs or vaccines within 12 months prior to the first dosing day.
  • •Treatment with radiation therapy or cytotoxic chemotherapeutic agents within 30 days of study drug administration or anticipated need for such treatment within the study.
  • •Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia; or other localized malignancies require agreement between the investigator and the study medical monitor for inclusion of the subject prior to randomization.
  • •Treatment with immunomodulating agents (such as systemic corticosteroids, interleukins, interferons) or any agent with known anti-HIV activity (such as hydroxyurea or foscarnet) within 30 days of study drug administration.
  • •An active Center for Disease Control and Prevention (CDC) Category C disease except cutaneous Kaposi's sarcoma not requiring systemic therapy during the trial.
  • •Treatment with any vaccine within 30 days prior to receiving study medication.
  • •Exclusion criteria for screening electrocardiogram (a single repeat is allowed for eligibility determination): Heart rate of <45 or >100 beats per minute (bpm) for males and <50 or >100 bpm for females; PR Interval of <120 or >200 milliseconds (msec) for both males and females; QRS duration of <70 or >110 msec for both males and females; QT interval corrected (QTc) for heart rate according to Fridericia's formula (QTcF) of >450 msec for males and >470 msec for females. A heart rate from 100 to 110 bpm can be rechecked by electrocardiogram or vitals within 30 minutes to verify eligibility. QTcF is either machine read or manually over-read.
  • •Any significant arrhythmia or electrocardiogram finding (e.g., prior myocardial infarction, sinoatrial pauses, bundle branch block, or conduction abnormality) which, in the opinion of the Investigator OR ViiV Medical Monitor, will interfere with the safety for the individual subject.

研究组 & 干预措施

Part 1: GSK3640254 10 mg

Experimental

Participants will receive GSK3640254 10 milligram (mg), capsules, orally for 10 days.

干预措施: GSK3640254 (Drug)

Part 1: GSK3640254 200 mg

Experimental

Participants will receive GSK3640254 200 mg, capsules, orally for 10 days.

干预措施: GSK3640254 (Drug)

Part 1: Placebo

Placebo Comparator

Participants will receive placebo capsules, orally for 10 days.

干预措施: Placebo matching GSK3640254 Mesylate salt (Drug)

Part 2: GSK3640254 40 mg

Experimental

Participants will receive GSK3640254 40 mg, capsules, orally for 7 days.

干预措施: GSK3640254 (Drug)

Part 2: GSK3640254 80 mg

Experimental

Participants will receive GSK3640254 80 mg, capsules, orally for 7 days.

干预措施: GSK3640254 (Drug)

Part 2: GSK3640254 140 mg

Experimental

Participants will receive GSK3640254 140 mg, capsules, orally for 7 days.

干预措施: GSK3640254 (Drug)

Part 2: Placebo

Placebo Comparator

Participants will receive placebo capsules, orally for 7 days.

干预措施: Placebo matching GSK3640254 Mesylate salt (Drug)

结局指标

主要结局

Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11

时间窗: Baseline (Day 1) and Day 11

Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. A HIV-1 RNA polymerase chain reaction (PCR) assay with a lower limit of detection (LLOD) of 50 copies per milliliter was used. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Part 2: Maximum Change From Baseline in Plasma HIV-1 RNA at Day 8

时间窗: Baseline (Day 1) and Day 8

Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. An HIV-1 RNA PCR assay with an LLOD of 50 copies per milliliter was used. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

次要结局

  • Part 1: Absolute Values for SBP and DBP(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST)(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Change From Baseline in Chemistry Parameters: Protein(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Calcium, Chloride, Phosphate, Potassium, Magnesium, Sodium, Urea, HDL Cholesterol, LDL Cholesterol(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Change From Baseline in Respiratory Rate(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Change From Baseline in Pulse Rate(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Change From Baseline in Hematology Parameter: Hemoglobin(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Change From Baseline in Hematology Parameter: Hematocrit(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Number of Participants With Non-SAEs and SAEs(Up to Day 12)
  • Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes, Platelet Count(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Change From Baseline in Hematology Parameter: Reticulocytes/Erythrocyte(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes, Platelet Count(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Number of Participants With Non-Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)(Up to Day 24)
  • Part 1: Change From Baseline in Hematology Parameter: Erythrocytes(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Change From Baseline in Hematology Parameter: Hemoglobin(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Change From Baseline in Hematology Parameter: Hematocrit(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Change From Baseline in Hematology Parameter: Erythrocytes(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Change From Baseline in Urinalysis Parameter: Urobilinogen(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Change From Baseline in Urinalysis Parameter: Potential of Hydrogen (pH)(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Change From Baseline in Urinalysis Parameter: Urobilinogen(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Change From Baseline in Respiratory Rate(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB), Corrected QT Interval Using Fridericia's Formula (QTcF)(Baseline (Day 1), Visit 5 (Days 8 to 10: Pre-dose, 2, 4 and 6 hours))
  • Part 2: Absolute Values for Hematology Parameter: Hemoglobin(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Change From Baseline in Hematology Parameter: Reticulocytes/Erythro(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Calcium, Chloride, Phosphate, Potassium, Magnesium, Sodium, Urea, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Change From Baseline in Chemistry Parameters: Creatinine, Bilirubin(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Change From Baseline in Chemistry Parameters: Amylase, Lipase(Baseline (Day 1) and Visit 6 (Day 11))
  • Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Bilirubin(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Change From Baseline in Chemistry Parameters: Protein(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Change From Baseline in Urinalysis Parameter: Specific Gravity(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcB, QTcF(Baseline (Day 1), Visit 5 (Day 7: Pre-dose, 2, 4 and 6 hours))
  • Part 2: Change From Baseline in Urinalysis Parameter: Specific Gravity(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Change From Baseline in Urinalysis Parameter: pH(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Change From Baseline in Pulse Rate(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Change From Baseline in SBP and DBP(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Absolute Values for Hematology Parameter: Hematocrit(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes, Platelet Count(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Absolute Values for Urinalysis Parameter: Urobilinogen(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Absolute Values for Urinalysis Parameter: pH(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Absolute Values for Urinalysis Parameter: Specific Gravity(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes, Platelet Count(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Absolute Values for Hematology Parameter: Erythrocytes(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Absolute Values for Hematology Parameter: Hematocrit(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Absolute Values for Hematology Parameter: Erythrocytes(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Absolute Values for Urinalysis Parameter: Urobilinogen(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Absolute Values for Respiratory Rate(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Absolute Values for Hematology Parameter: Hemoglobin(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Absolute Values for Chemistry Parameters: Creatinine, Bilirubin(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Absolute Values for Pulse Rate(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Absolute Values for Hematology Parameter: Reticulocytes/Erythro(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Calcium, Chloride, Phosphate, Potassium, Magnesium, Sodium, Urea, HDL Cholesterol, LDL Cholesterol(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Absolute Values for Chemistry Parameters: ALT, ALP, AST(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Absolute Values for Hematology Parameter: Reticulocytes/Erythro(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Absolute Values for Chemistry Parameters: Protein(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 1: Absolute Values for Chemistry Parameters: Amylase, Lipase(Baseline (Day 1) and Visit 6 (Day 11))
  • Part 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Calcium, Chloride, Phosphate, Potassium, Magnesium, Sodium, Urea, HDL Cholesterol, LDL Cholesterol(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Absolute Values for Chemistry Parameters: Creatinine, Bilirubin(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Absolute Values for Chemistry Parameters: Protein(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Absolute Values for Chemistry Parameters: Amylase, Lipase(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Absolute Values for Urinalysis Parameter: Specific Gravity(Baseline (Day 1) and Visit 5 (Days 8 to 10))
  • Part 2: Absolute Values for Urinalysis Parameter: pH(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Absolute Values for SBP and DBP(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Absolute Values for Respiratory Rate(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 2: Absolute Values for Pulse Rate(Baseline (Day 1) and Visit 5 (Day 7))
  • Part 1: Absolute Values for ECG Parameters: PR, QRS, QT, QTcB and QTcF Intervals(Baseline (Day 1), Visit 5 (Days 8 to 10: Pre-dose, 2, 4 and 6 hours))
  • Part 1: Maximum Observed Concentration (Cmax) Following Administration of GSK3640254 on Day 1(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1: Time to Maximum Observed Concentration (Tmax) Following Administration of GSK3640254 on Day 1(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1: Concentration at 24 Hours Post-dose (C24) Following Administration of GSK3640254 on Day 1(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: Absolute Values for ECG Parameters: PR, QRS, QT, QTcB and QTcF Intervals(Baseline (Day 1), Visit 5 (Day 7: Pre-dose, 2, 4 and 6 hours))
  • Part 1: Area Under the Plasma Concentration Time Curve From Zero to 24 (AUC[0-24]) Following Administration of GSK3640254 on Day 1(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1: Absorption Lag Time (Tlag) Following Administration of GSK3640254 on Day 1(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: AUC(0-24) Following Administration of GSK3640254 on Day 1(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: Tmax Following Administration of GSK3640254 on Day 1(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1: Cmax Following Repeat Dose Administration of GSK3640254 on Days 8 to 10(Days 8 to 10: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: CL/F Following Repeat Dose Administration of GSK3640254 on Day 7(Day 7: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1 and Part 2: Change From Baseline in Plasma HIV-1 RNA Relative to Day 8 AUC(0-tau)(Baseline (Day 1) and Day 8)
  • Part 1 and Part 2: Change From Baseline in Plasma HIV-1 RNA Relative to Day 8 Cmax(Baseline (Day 1) and Day 8)
  • Part 2: Cmax Following Administration of GSK3640254 on Day 1(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: Tlag Following Administration of GSK3640254 on Day 1(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1: Concentration at End of Dosing Interval (Ctau) Following Repeat Dose Administration of GSK3640254 on Days 8 to 10(Days 8 to 10: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1 and Part 2: Dose Proportionality of GSK3640254 Administered on Day 1 Based on AUC(0-24)(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1 and Part 2: Dose Proportionality of GSK3640254 Administered on Day 1 Based on Cmax(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: C24 Following Administration of GSK3640254 on Day 1(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1: Pre-dose Concentration (C0) Following Repeat Dose Administration of GSK3640254 on Days 8 to 10(Days 8 to 10: Pre-dose)
  • Part 1 and Part 2: Dose Proportionality of GSK3640254 Following Repeat Dose Administration Based on Cmax(Days 8 to 10: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose; Day 7: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1 and Part 2: Dose Proportionality of GSK3640254 Following Repeat Dose Administration Based on Ctau(Days 8 to 10: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose; Day 7: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1: Area Under the Plasma Drug Concentration-time Curve From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) Following Repeat Dose Administration of GSK3640254 on Days 8 to 10(Days 8 to 10: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1: Tmax Following Repeat Dose Administration of GSK3640254 on Days 8 to 10(Days 8 to 10: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1: Apparent Terminal Phase Half-life (t1/2) Following Repeat Dose Administration of GSK3640254 on Days 8 to 10(Days 8 to 10: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: AUC(0-tau) Following Repeat Dose Administration of GSK3640254 on Day 7(Day 7: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: Cmax Following Repeat Dose Administration of GSK3640254 on Day 7(Day 7: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: Tmax Following Repeat Dose Administration of GSK3640254 on Day 7(Day 7: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1: Apparent Oral Clearance (CL/F) Following Repeat Dose Administration of GSK3640254 on Days 8 to 10(Days 8 to 10: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: C0 Following Repeat Dose Administration of GSK3640254 on Day 7(Day 7: Pre-dose)
  • Part 2: Ctau Following Repeat Dose Administration of GSK3640254 on Day 7(Day 7: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: t1/2 Following Repeat Dose Administration of GSK3640254 on Day 7(Day 7: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1 and Part 2: Change From Baseline in Plasma HIV-1 RNA Relative to Day 8 Ctau(Baseline (Day 1) and Day 8)
  • Part 1: Accumulation Ratio Following Repeat Dose Administration of GSK3640254(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose; Days 8 to 10: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 2: Accumulation Ratio Following Repeat Dose Administration of GSK3640254(Days 1 and 7: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1 and Part 2: Dose Proportionality of GSK3640254 Administered on Day 1 Based on C24(Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)
  • Part 1 and Part 2: Dose Proportionality of GSK3640254 Following Repeat Dose Administration Based on AUC(0-tau)(Days 8 to 10: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose; Day 7: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours post-dose)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
1 期
GSK3640254 First Time in Human (FTIH) Study in Healthy VolunteersInfection, Human Immunodeficiency VirusHIV Infections
NCT03231943ViiV Healthcare78
已完成
不适用
Cohort Field Study to Assess the Safety and Efficacy of the PrePex Device for Non-Surgical Circumcision When Performed by NursesMale CircumcisionHIV Prevention
NCT01434628Ministry of Health, Rwanda590
招募中
早期 1 期
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDSHIV-1
NCT06252402City of Hope Medical Center15
Unknown
3 期
Trial of SAVVY Vaginal Gel and HIV in NigeriaHIV Infections
NCT00130078Biosyn2,142
招募中
2 期
Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 ReservoirHIV-1-infection
NCT06640192Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal24